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The Flaws of Immunosuppression in 
Organ Transplantation Today 
T. E. Starzl 
M y CHARGE in opening this session is to define some of the major prob-
lems in organ transplantation today, an 
order for which there is not enough time. 
For example, it would be possible to spend 
20 mill talking about developments in tissue 
typing and organ preservation, and the 
practical interrelationships of those two 
areas of endeavor. The complicating role 
of presensitization states is another topic 
of enormous pragmatic concern. 
I want, instead, to look mainly at a dif-
ferent problem, but the one that gives trans-
plantation uniqueness and that is central to 
a myriad of secondary difficulties. I am re-
ferring, of course, to immunosuppression. 
In the context of my instructions, there 
is no point to speak glowingly of what has 
been achieved in the development of clin-
ically useful immunosuppression. That is 
the well-known basis of our still-young spe-
cialty. Instead, my obligation is to empha-
size what has not been achieved. Broadly 
speaking, there are two defective areas. 
DEFIC IENCIES OF TRANSPLANTATION 
First, the predictability of treatment is 
imperfect. A reasonably accurate prognosis 
can be offered only to recipients of per-
fectly matched sibling kidneys. But even 
here there is an occasional unexpected graft 
loss from rejection that cannot easily be ex-
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plained despite intensive retrospective 
study. Using other relatives than perfectly 
matched sibling donors, the predictability 
of rejection control is substantially less. 
When cadaveric organs are transplanted, 
the situation becomes too much like a lot-
tery. Some patients have uncontrolled re-
jection, others have no difficulty at all, and 
about half are intermediate between these 
extremes. 
In the cadaveric situation, kidney sur-
vival at I year using any of the presently 
employed regimens is seemingly more or 
less fixed at about 50% to 70% in all the 
world's great transplantation centers. The 
exact success rate is influenced to some ex-
tent by the inclusion or exclusion of can-
didates who have a high risk because of ad-
vanced age, coincident disease, or other 
factors. 
The second general defect is related to the 
first. At the present time, even patients who 
eventually achieve a perfect transplant re-
sult often must first pass through a post-
operative period of significant morbidity. 
The requirement for intensive immuno-
suppression is greatest early after trans-
plantation. Because the steroids are the 
only highly dose-maneuverable component 
of the immunosuppressive regimens pres-
ently employed, the intensification of ther-
apy translates inevitably into larger quanti-
ties of prednisone. If high-dose steroid 
therapy can be avoided or kept to a brief 
duration while at the same time maintain-
ing good homograft function, the result is 
apt to be spectacularly successful. If ster-
oids are needed chronically, their well-
known side effects depreciate the value of 
post-transplantation life or may threaten 
survival itself. 
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THE INGREDIENTS OF SUCCESS 
In successful cases, a characteristic train 
of events is usually observed. To start with, 
if acute rejection occurs, it is readily and 
completely controlled with vigorous steroid 
treatment. Thereafter, prompt reduction of 
prednisone therapy is possible without 
graft deterioration. The fact that the re-
quired immunosuppression often eventually 
becomes lower than that which failed to 
control rejection at the outset has led many 
to conclude that a dynamic process of graft 
"acceptance" often transpires. The neces-
sary combination of factors is apparently 
the continuously present antigen of the 
graft plus immunosuppression. The two 
main, although not mutually exclusive, 
mechanisms of graft acceptance have been 
envisioned as tolerance induction by de-
pletion of specific lines of selectively sus-
ceptible lymphoid cells leading to tolerance 
or enhancement by antigraft antibodies} 
The Seattle transplantation group headed 
by Marchioro, using the techniques de-
veloped by the Hellstroms, has demon-
strated changing host-graft relationships in 
kidney recipients that are consistent with 
the multifactorial graft-acceptance hy-
pothesis.2 
Let me restate the two clinically impor-
tant propositions I have already mentioned. 
First, the present-day transplant recipient 
must face a kind of risk that is not precisely 
analyzable in advance. The transplantation 
itself is a ruthless test system that weeds 
out the biologically unsatisfactory recipient 
or at least the unsatisfactory donor-recip-
ient combinations. Second, even in success-
ful cases there is an interval of early post-
operative peril, although this risk is not 
fixed since the donor-recipient immuno-
logic relationship is subject to change dur-
ing the first weeks or months of care. 
Given these conditions, it is not surpris-
ing that all life-survival curves from 1962 to 
the present show the major patient and kid-
ney losses in the first 3 to 12 postoperative 
months. In our own first 64 consecutive 
cases collected between the autumn of 1962 
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and March 1964, only 37 kidney recipients 
were left at the end of I year. After 3,5, and 
10 years, 32, 31, and 26 of these patients 
were still well and in almost all instances 
with good renal function. There are still 26 
survivors, now after wi to 12 years, who 
represent about half of the world's renal 
transplant recipients living after transplan-
tation in the era before the spring of 1964.3 
The results in these early trials were in-
comparably better with related than with 
unrelated transplantations. 
Through succeeding years patient sur-
vival has been significantly improved, es-
pecially in unrelated (now always cadaveric) 
cases. These improvements undoubtedly 
have derived in part from more clever ma-
nipulation of the original drug combination 
of azathioprine and prednisone, which to-
gether made possible what has been termed 
the modern era of transplantation. Never-
theless, the pattern of early losses is identi-
fiable, though less extreme. 
Increased survival has been seen in some 
centers such as ours, at about the same time 
as the introduction of heterologous anti-
lymphocyte globulin as the third com-
ponent of what has become known as triple-
drug therapy. Although ALG is a potent 
immunosuppressive agent in man, its role in 
clinical transplantation, and even whether 
it adds significantly to kidney or patient 
survival after renal transplantation, is still 
unresolved. It has become clear as the years 
have passed that the only indispensable 
constituent of any drug combination used 
in the last dozen years is the steroid one. 
Even azathioprine, formerly considered the 
cornerstone of therapy, can be replaced 
with cyclophosphamide. But nothing has 
been found to replace steroids. Without 
steroids, the field of transplantation as it is 
presently practiced would disappear tomor-
row. 
THE PROSPECTS OF IMPROVEMENT 
The drug combinations that include 
azathioprine, prednisone, cyclophospha-
mide, and ALG have evolved into the well-
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FLAWS OF IMMUNOSUPPRESSION 
known double- or triple-drug cocktails that 
have been used the world over. All are vari-
ations on the same theme of daily conserva-
tive therapy beginning with operation, with 
subsequent responses with steroids if there 
is rejection. Although much has been 
thereby accomplished, I do not believe fur-
ther small adjustments in dosage and sched-
ule are going to correct the deficiencies of 
transplantation that I mention~d at the out-
set. Some drastic changes in approach are 
going to be needed. I conceive the objective 
to be a very great foreshortening of the 
graft acceptance process, so that the trans-
plant passes through this danger period in 
a few days instead of a few weeks or 
months. 
How can this be accomplished? The first 
step is to acknowledge that our present 
methods of treatment represent only a half-
way station toward acceptable clinical stan-
dards. In our field, there is a surprising re-
sistance by clinicians to change. In turn, the 
proportion of clinical transplanters who re-
tain a lively interest in laboratory experi-
mentation has declined. Finally, the stan-
dard approaches to immunosuppression I 
outlined a few moments ago have become 
so well accepted that deviations from them 
are going to be submitted to close scrutiny 
in the increasingly rigid administrative 
matrix in which we practice. 
Be that as it may, and admitting now to 
personal prejudice, I am looking forward 
to some practical clinical applications of 
the kind of work with tolerance induction 
that Monaco and his associates have re-
ported in rodents, dogs, and at least I hu-
man. Under immunosuppression they have 
administered intravenous bone-marrow 
cells in close temporal relationship to the 
transplantation of kidneys.4 In dogs, the 
renal grafts survived many times longer 
than with conventional therapy. Similar or 
related work has been carried out by Rapa-
port,S Lance and Medawar,6 Brent,7 and 
Iwasaki,s to give a very incomplete list. It 
is interesting that Kelly of the University of 
Minnesota attempted the contemporaneous 
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transplantation of lymphoid cells plus kid-
ney homografts more than a decade ago. 
Their clinical trial was abandoned when, in 
some cases, the magnitude of kidney re-
jection seemed to be made worse.9 
The other approach is the use of passive 
or active enhancement. Many laboratory 
groups are working to exploit the immuno-
suppressive properties of antigraft anti-
bodies.1O Four years ago at The Hague, 
Batchelor told us of the first clinical use of 
enhancement. Of necessarily great concern 
here also is the possibility that therapy 
could injure the transplant by the direct ac-
tion of the antibodies. 
These efforts at tolerance induction and 
enhancement are obviously designed to 
mimic and accelerate the mechanisms by 
which it has been speculated that grafts are 
accepted under present-day therapy. The 
same drugs should make this possible 
(azathioprine, cyclophosphamide, ALG, 
and steroids), but I think these agents 10 
years from now will be used in a very dif-
ferent way. I envision high-dose pulse ther-
apy with long intervening treatment-free 
intervals and thus liberation of the patient 
from much of the chronic morbidity in-
herent in our present approach. 
With renal transplantation, a high order 
of patient service can be provided today 
despite the limitations of immunosuppres-
sion so well known to all of us. The reason 
is that it is so easy to return patients to 
chronic dialysis if too much immunosup-
pression is required to retain homograft 
function. The same is not true for the liver, 
heart, and lung, for which artificial organ 
backup is not available. Using these organs, 
transplant and patient survival are nearly 
synonymous. 
EXTRARENAL ORGANS 
With the heart, the transplantation itself 
has no troublesome technical problems, and 
in Shumway's magnificent series the life-
survival curve reflects very accurately the 
ability to control cardiac rejection. The 
I-year survival has edged up to about 50% 
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in the Stanford series. Substantial further 
improvement will await the kind of ad-
vances in immunosuppression that I hope 
will be forthcoming. 
It is probable that the liver is immuno-
logically "easier" than either the kidney or 
heart, but the technical problems are far 
from solved. In our own experience we be-
lieve that the leading causes of death are 
technical misadventures. At the David 
Hume Memorial Symposium a few months 
ago, we showed that about a third of all the 
deaths after our liver transplantations were 
due in one way or another to troubles with 
bile duct reconstruction. Septic problems 
secondary to biliary duct complications 
proved particularly lethal. Early diagnosis 
of defective biliary drainage by transhepatic 
cholangiography with or without biopsy is 
the only way I know to make the necessary 
differential diagnosis in the patient who be-
comes jaundiced after liver transplantation. 
If intrahepatic ducts are dilated, prompt re-
operation must be done. 
With both the liver and lung, it is un-
likely that a clear distinction between tech-
nical, infectious, and rejection problems will 
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be possible until a much more reliable 
method is available for the promotion of 
graft acceptance. Then if something goes 
wrong it can be assumed that rejection is 
not the cause. Today the obverse assump-
tion must always be made that rejection is 
responsible. 
SUMMARY 
In closing, no one denies that renal trans-
plantation is a practical venture. Still, few 
would dare to assert that it is perfected. 
Using present regimens of immunosuppres-
sion, further exploitation of transplantation 
of extrarenal organs is not going to be pos-
sible without better treatment. With all 
organs there is a great need to look forward 
and not back, to emphasize to our basic 
science colleagues how dissatisfied we are, 
to not accept our present standards of care 
so rigidly that departures will be considered 
heretical by peer review groups, and to re-
turn to the laboratories ourselves if only to 
empirically test therapeutic regimens and 
modifications that are quite different than 
those now current. 
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